This protocol follows the guidelines of Lifenet Health's ethics committee. The manuscript does not contain any studies with human participants or animal studies performed by any of the authors. All cells were isolated from donor tissue fully consented for research purposes by Lifenet Health.
1. Medium preparation
2. Thawing, counting, and plating human feeder cells (Figure 1A)
3. Thawing, counting, and plating primary human hepatocytes (Figure 1B)
4. Maintenance
5. Collection of culture supernatant samples for measurement of albumin and urea
6. Staining day I
CAUTION: Fixation buffer contains Paraformaldehyde. Paraformaldehyde can cause eye damage, skin irritation, and organ toxicity. Work in an area with good ventilation and wear appropriate personal protection equipment (PPE).
7. Staining day II
8. ImageJ analysis (Figure 2)
NOTE: It is recommended to use ImageJ Version 1.52a or higher.
9. Quantitation of total attached hepatocytes and percent attachment (Plateability)
10. Albumin assay
11. Urea assay
CAUTION: Blood urea nitrogen (BUN) acid reagent contains sulfuric acid. The sulfuric acid concentration in the BUN acid reagent is considered corrosive. Do not ingest. Work in an area with good ventilation and wear appropriate PPE.
The overall method of plating, culturing, and basic functionality testing of the hepatic culture system involves common primary cell culture techniques and analysis, as illustrated in Figure 1. Hepatocyte attachment and percent plateability were calculated on day 14 using ImageJ analysis of at least five images of Cytokeratin 18 and DAPI staining per well (Figure 2). Representative images of PHHs cultured with feeder cells are shown in Figure 3. The various hepatic seeding densities showed visual differences of confluence based on seeding density and maintained typical hepatic, cuboidal morphology for 14 days of culture. Images of hepatocyte donor lots A and B were captured for each tested seeding density (Figure 4A). The average percent plateability for donor B (89.04% ± 3.99%, 198,552 ± 49,885 PHHs) was higher than donor A (66.08% ± 6.67%, 146,128 ± 33,063 PHHs) across all seeding densities used (Figure 4B). Donor A had significantly higher percent plateability using 150,000 PHHs/well (76.07% ± 12.87%) compared to 250,000-300,000 PHHs/well (62.75% ± 9.64%). Donor B showed no significant differences in hepatocyte percent plateability. Donor B had the lowest hepatocyte plateability (85.78% ± 13.25%) at the highest seeding density, 300,000 PHHs/well. Similar to donor A, seeding donor B at 150,000 PHHs/well had the highest percent plateability of hepatocytes (94.75% ± 15.07%).
Albumin production and urea synthesis were measured at three time points during the 14-day culture period and normalized to calculated attached hepatocytes. Overall, donor A had increased albumin production compared to donor B (41.32 ± 4.58 µg alb/day/106 PHHs vs. 34.66 ± 10.03 µg alb/day/106 PHHs) (Figure 5). Donors A and B had the highest albumin production seeding hepatocytes at 150,000 PHHs/well, 45.91 ± 5.96 µg alb/day/106 PHHs and 48.67 ± 20.44 µg alb/day/106 PHHs, respectively. No significant differences in albumin production were seen in the seeding densities used. As stated by Baudy et al.3, it is desirable that liver microphysiological systems maintain consistent albumin production and urea synthesis with less than 50% change over 14 days of culture. The coefficient of variation (CV) was calculated by dividing the mean by the standard deviation for days 7, 10, and 14. All samples were run in duplicates. The CV for albumin output over the 14-day culture period at 150,000 PHHs/well was 12.24% for donor A and 37.97% for donor B, less than the 50% criterion desired. A high variance in albumin production was seen in both donor A and donor B when seeded at 250,000 and 300,000 PHHs/well. At these seeding densities, both donors experience a steep decrease in albumin production between days 7, 10, and 14 of culture (CV donor A, 22.49%, and donor B, 45.07%).
Donor B urea synthesis (95.09 ± 18.91 µg urea/day/106) was increased compared to donor A (64.92 ± 4.66 µg urea/day/106 PHHs) when averaging days 7, 10, and 14 PHH lot specific data (Figure 6). Donor B (113.49 ± 37.34 µg urea/day/106 PHHs) and donor A (69.12 ± 17.06 µg urea/day/106 PHHs) had the greatest urea synthesis over a 14-day culture period seeding at a density of 150,000 PHHs/well and 200,000 PHHs/well, respectively. Both donor lots had the lowest urea output and highest CV at 300,000 PHHs/well. No significant differences in urea synthesis were seen in the seeding densities used. The lowest CV for urea synthesis for donor A was seen when cultured at 250,000 PPHs/well (23.11%) and 200,000 PHHs/well for donor B (28.26%). As highlighted by these results, optimal seeding density for a given lot of PHH depends on the level of confluency desired at the time of the assay and the nature of the outcomes that are being measured; higher seeding density may not always correlate with higher signal or dynamic range.
Figure 1: Flow chart of plating, culturing, and functional testing of hepatocytes with feeder cells. (A) Feeder cells are thawed in a specific thawing medium (see Table of Materials), resuspended in a complete plating medium (see Table of Materials), and the cells are counted. The cells are diluted, plated, and incubated for 60 min at 37 °C/5% CO2. (B) Hepatocytes are thawed in a specific thawing medium (see Table of Materials), resuspended in a complete plating medium, and the cells are counted. The hepatocytes are diluted and plated with feeder cells. The cells are incubated for 2-4 h at 37 °C/5% CO2, shaking in a N-S-E-W motion every 15 min for the first 60 min of culture. The plating medium is replaced with a pre-warmed complete culture medium for maintenance of culture (see Table of Materials). The cultures are fed daily. (C) On days 7, 10, and 14, medium samples are collected for albumin and urea testing. Following collection of samples on day 14, the cells are fixed and stained with Cytokeratin 18 (see Table of Materials) antibody 16-24 h at 4 °C. Further, they are incubated in an appropriate secondary antibody, washed, and mounted with DAPI (see Table of Materials) for capturing and image analysis. Please click here to view a larger version of this figure.
Figure 2: Image analysis using ImageJ software. ImageJ processing of captured images. Step 1: a scale is applied to all images based on the microscope-specific scale bar. Step 2: the image type is changed. Step 3: a threshold limit is applied to select DAPI particles. Step 4: a particle analysis is performed, and the count is recorded. Step 5: to determine the number of attached feeder cells, a merged image is counted using the multi-point tool. Please click here to view a larger version of this figure.
Figure 3: Morphology of various hepatic seeding densities cultured with feeder cells. Representative images on days 7 and 14 of PHHs cultured with feeder cells (50,000 cells/well) at hepatic seeding densities of 150,000, 200,000, 250,000, and 300,000 PHHs/wells. Images were taken using a 10x objective lens on an inverted phase contrast microscope. Scale bar = 100 µm. Please click here to view a larger version of this figure.
Figure 4: Fluorescent Immunocytochemistry of various hepatic seeding densities cultured with feeder cells. (A) Representative images of Cytokeratin 18 (red) staining on day 14 at hepatic seeding densities of 150,000, 200,000, 250,000, and 300,000 PHHs/wells. Two-wells for each seeding density were fixed for 30 min at 4 °C. Wells were incubated 16-24 h at 4° C with primary antibody at 1:1000. A secondary antibody was used at 1:500 for 30 min at 4 °C in dark. DAPI (blue) nuclear stain was added to wells for 15 min at room temperature. Images were taken using a 10X objective lens on an inverted fluorescent microscope. Scale bar = 100 µm. (B) Calculated attached hepatocytes and percent plateability of various hepatic seeding densities calculated using ImageJ. *p ≤ 0.05, to percent plateability for 200,000, 250,000, and 300,000 PHHs/well. Error bars represent standard deviation (n ≥ 5 images per condition). Please click here to view a larger version of this figure.
Figure 5: Albumin production of hepatocytes cultured with feeder cells. Albumin production from hepatic seeding densities at 150,000, 200,000, 250,000, and 300,000 PHHs/well. Columns represent the 14-day average of micrograms of albumin/day normalized to total attached hepatocytes. A line represents CV between days 7, 10, and 14. Error bars represent standard deviation (n ≥ 2 wells per condition with replicates). Please click here to view a larger version of this figure.
Figure 6: Urea synthesis of hepatocytes cultured with feeder cells. Urea synthesis from hepatic seeding densities at 150,000, 200,000, 250,000, and 300,000 PHHs/well. Columns represent 14-day average of µg urea/day normalized to total attached hepatocytes. A line represents %CV between days 7, 10 and 14. Error bars represent standard deviation (n ≥ 2 wells per condition with replicates). Please click here to view a larger version of this figure.
Standard (S) # | Concentration (µg/mL) | Urea Solution (µL) | Complete Culture (µL) |
1 | 100 | 53.3 75 mg/dL stock |
346.7 |
2 | 50 | 100 (S1 solution) |
100 |
3 | 25 | 100 (S2 solution) |
100 |
4 | 12.5 | 100 (S3 solution) |
100 |
5 | 6.26 | 100 (S4 solution) |
100 |
6 | 3.125 | 100 (S5 Solution) |
100 |
7 | 1.5625 | 100 (S6 Solution) |
100 |
Blank | 0 | 0 | 100 |
Table 1: Urea standard sample preparation. Using 75 mg/dL stock urea, prepare a 100 µg/mL urea solution. Aliquot the suggested volumes to reach the final concentration for the standard curve.
0.2 µm PES filter unit | Thermo Fisher Scientific | 565-0020 | User preference |
15 mL or 50 mL conical tubes | Thermo Fisher Scientific | 352196 or 352070 | User preference |
Alexa Fluor 555, goat anti-rabbit | Thermo Fisher Scientific | A-21428 | Other secondary antibodies can work |
Anti-Cytokeratin 18 antibody | abcam | ab24561 | Necessary using same dilution |
AOPI | Nexcelom | CS2-0106-5mL | Used for Cellometer counting |
Biosafety cabinet | Labconoco | 3460801 | User preference |
Black-walled, clear bottom, 96-well plate | Thermo Fisher Scientific | 165305 | User preference |
Centrifuge | Thermo Fisher Scientific | Sorvall X4R | Capable of speeds up to 400 x g |
Collagen coated plate, 24-well | Greiner Bio-One | 662950 | Rat tail collagen coating |
Counting slides | Nexcelom | CHT4-SD100-002 | Used for Cellometer counting |
Culture medium | LifeNet Health | MED-TCCM | |
Culture supplement | LifeNet Health | MED-TCSC | |
DAPI | Thermo Fisher Scientific | 00-4959-52 | Contains mounting medium |
DPBS (-Ca, -Mg) | Thermo Fisher Scientific | 14190250 | User preference |
Feeder cell supplement | LifeNet Health | MED-TCSA | |
Feeder cell thawing medium | LifeNet Health | MED-FCTM | |
Fluorescent microscope | Zeiss | AxioObserver Z1 | Equipped with user specific filters |
Hepatocyte thawing medium | LifeNet Health | MED-HHTM4C-50ML | |
Human albumin ELISA kit | abcam | ab108788 | Necessary if using same dilution |
Human feeder cells | LifeNet Health | PHFC24 | |
Humidified incubator | VWR | 97025-842 | Capable of 5% CO2 |
IC Fixation buffer | Thermo Fisher Scientific | 00-8222-49 | Paraformaldehyde based, 10% formalin can also be used |
ImageJ | National Insitute of Health | Version 1.52a | 1.52a or higher |
Inverted phase contrast microscope | Olympus | CK40-F100 | User preference |
Microcentrifuge tubes | VWR | 20170-022 | User preference |
Micropipettes (various sizes) | USA Scientific | ErgoOne | User preference |
Permeabilization buffer (10x) | Thermo Fisher Scientific | 00-8333-56 | Other permeabilization buffers can work |
Plate reader | BMG Labtech | CLARIOstar | Capable of reading absorbance 450-640 nm |
Plating medium | LifeNet Health | MED-TCPM | |
Plating supplement | LifeNet Health | MED-TCSB | |
Primary human hepatocytes | LifeNet Health | various | Catalog number may vary based on lot number |
Secondary antibody | Thermo Fisher Scientific | A-21428 | User preference |
Serological pipet controller | Gilson | F110120 | User preference |
Storage bottle 100–500 mL | VWR | 76311-770 | User preference |
Urea Nitrogen (BUN) Test | Stanbio | 0580-250 | |
Water bath | PolyScience | WBE05 | Capable for use at 37 °C |
Finding a long-term, human-relevant culture model for primary human hepatocytes (PHHs) for pharmacological and toxicological studies remains a challenge. Current in vitro model platforms are often inconvenient and complex, lack phenotypic stability over time, and do not support multiple PHH lots, lacking experimental reproducibility and flexibility. Here, we provide a detailed protocol for the thawing, plating, and maintenance of an all-human 2D+ hepatic system (TV2D+), which takes advantage of standard two-dimensional (2D) culture techniques and equipment while maintaining the longevity and phenotypic stability over time that typically accompany more complex three-dimensional (3D) systems. The results show attachment and percent plateability in TV2D+ as a function of PHH seeding density, as well as stable functionality for at least 2 weeks in culture. A range of PHH seeding densities are assessed to achieve a successful long-term culture. When established properly, the PHHs in TV2D+ organize into hepatocyte colonies, express a hepatic-specific marker, and maintain viability, architectural integrity, and physiologically relevant levels of albumin and urea. This unique combination of attributes makes the TV2D+ system a suitable hepatic model for a variety of pharmacological and toxicological applications.
Finding a long-term, human-relevant culture model for primary human hepatocytes (PHHs) for pharmacological and toxicological studies remains a challenge. Current in vitro model platforms are often inconvenient and complex, lack phenotypic stability over time, and do not support multiple PHH lots, lacking experimental reproducibility and flexibility. Here, we provide a detailed protocol for the thawing, plating, and maintenance of an all-human 2D+ hepatic system (TV2D+), which takes advantage of standard two-dimensional (2D) culture techniques and equipment while maintaining the longevity and phenotypic stability over time that typically accompany more complex three-dimensional (3D) systems. The results show attachment and percent plateability in TV2D+ as a function of PHH seeding density, as well as stable functionality for at least 2 weeks in culture. A range of PHH seeding densities are assessed to achieve a successful long-term culture. When established properly, the PHHs in TV2D+ organize into hepatocyte colonies, express a hepatic-specific marker, and maintain viability, architectural integrity, and physiologically relevant levels of albumin and urea. This unique combination of attributes makes the TV2D+ system a suitable hepatic model for a variety of pharmacological and toxicological applications.
Finding a long-term, human-relevant culture model for primary human hepatocytes (PHHs) for pharmacological and toxicological studies remains a challenge. Current in vitro model platforms are often inconvenient and complex, lack phenotypic stability over time, and do not support multiple PHH lots, lacking experimental reproducibility and flexibility. Here, we provide a detailed protocol for the thawing, plating, and maintenance of an all-human 2D+ hepatic system (TV2D+), which takes advantage of standard two-dimensional (2D) culture techniques and equipment while maintaining the longevity and phenotypic stability over time that typically accompany more complex three-dimensional (3D) systems. The results show attachment and percent plateability in TV2D+ as a function of PHH seeding density, as well as stable functionality for at least 2 weeks in culture. A range of PHH seeding densities are assessed to achieve a successful long-term culture. When established properly, the PHHs in TV2D+ organize into hepatocyte colonies, express a hepatic-specific marker, and maintain viability, architectural integrity, and physiologically relevant levels of albumin and urea. This unique combination of attributes makes the TV2D+ system a suitable hepatic model for a variety of pharmacological and toxicological applications.